Last reviewed · How we verify
Whole blood transfusion
Whole blood transfusion is a Biologic drug developed by Oregon Health and Science University. It is currently in Phase 3 development for Treatment of anemia due to blood loss or bone marrow failure, Treatment of bleeding disorders, such as hemophilia, Treatment of other conditions related to blood loss or anemia.
Whole blood transfusion involves the transfer of whole blood from a donor into a patient to restore blood volume and red blood cell count.
Whole blood transfusion involves the transfer of whole blood from a donor into a patient to restore blood volume and red blood cell count. Used for Treatment of anemia due to blood loss or bone marrow failure, Treatment of bleeding disorders, such as hemophilia, Treatment of other conditions related to blood loss or anemia.
At a glance
| Generic name | Whole blood transfusion |
|---|---|
| Sponsor | Oregon Health and Science University |
| Modality | Biologic |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
This process helps to replenish oxygen-carrying red blood cells, clotting factors, and other essential components of blood. The transfused blood can help to alleviate symptoms of anemia, bleeding disorders, and other conditions related to blood loss.
Approved indications
- Treatment of anemia due to blood loss or bone marrow failure
- Treatment of bleeding disorders, such as hemophilia
- Treatment of other conditions related to blood loss or anemia
Common side effects
- Hypersensitivity reactions
- Acute hemolysis
- Transmission of infectious diseases
Key clinical trials
- Improving White Blood Cell Collection From Healthy Donors (PHASE4)
- Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (PHASE1, PHASE2)
- Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy (NA)
- Study of Transfusion-Transmitted Infections
- HIFU Versus Myomectomy for the Treatment of Symptomatic Uterine Fibroids (NA)
- Hemoglobin Drop and Need for Blood Transfusion in Primary Knee Arthroplasty With or Without Drain Insertion (NA)
- Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide (EARLY_PHASE1)
- ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Whole blood transfusion CI brief — competitive landscape report
- Whole blood transfusion updates RSS · CI watch RSS
- Oregon Health and Science University portfolio CI
Frequently asked questions about Whole blood transfusion
What is Whole blood transfusion?
How does Whole blood transfusion work?
What is Whole blood transfusion used for?
Who makes Whole blood transfusion?
What development phase is Whole blood transfusion in?
What are the side effects of Whole blood transfusion?
Related
- Manufacturer: Oregon Health and Science University — full pipeline
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Treatment of anemia due to blood loss or bone marrow failure
- Indication: Drugs for Treatment of bleeding disorders, such as hemophilia
- Indication: Drugs for Treatment of other conditions related to blood loss or anemia
- Compare: Whole blood transfusion vs similar drugs
- Pricing: Whole blood transfusion cost, discount & access